Off-label use of implantable devices and stents in congenital heart disease patient’s interventional procedures. a single center experience Authors: Amira Nour, Maiy El sayed, Azza Elfiky, Hebattallah Attia, Alaa Roshdy, Yasmeen Abdelrazik, Amr Mansour Published: 2025 ABSTRACT AbstractBackgroundThere have been great advances in the field of congenital heart disease (CHD) catheter intervention. Diseases that were previously considered only with surgical treatment options are now treated percutaneously with high success rates. However, devices used in this fields are referred to being used in an off-labeled fashion, as they were not originally developed for this purpose. This is the result of many factors among which the broad spectrum morphological and clinical expression of CHD.ObjectiveThe aim of this paper is to describe the prevalence, types of procedures and outcomes of the off-label use of implantable devices and stents in the CHD patient’s interventional procedure in our center.MethodsA retrospective data involving all patients who were referred to congenital and structural heart disease unit in our institution for catheter based interventional procedures in the last 4 years based on our medical records. Patients’ demographic data, diagnosis, procedural data, type of devices used, follow-up data and incidence of major and minor complications were recorded to calculate the success and incidence of complications in this cohort of patient.ResultsA total number of 410 patients underwent a percutaneous interventional procedure with the use of an off-label device or stent, out of a total of 2530 interventional procedure during the last 4 years, accounting for approximately 21.5% of all device and stents implanted during this period. The mean age of patients was 6.70 ± 4.47 years, the mean body weight was 18 0.3 +/- 8.5 kg. The procedures were versatile and included Ventricular septal defect (VSD) closure, Persistent ductus arteriosus (PDA) closure, aorto-pulmonary (AP) collaterals embolization, coronary arteriovenous (AV) fistula closure, veno-venous collaterals closure, pulmonary AV malformation closure, PDA stenting, and right ventricular outflow tract (RVOT) stenting. Implantable devices were used in 360 patients (87.8%) while Stents were implanted off-label in 50 patients (12.2%). Device-related complications were reported in 13 patients: seven major complications (device embolization in 3 cases, stent malposition in 2 and stent embolization in another 2 patients) and 6 minor complications ( mild left pulmonary artery stenosis, mild tricuspid and aortic valve regurgitation, residual VSD with hemolysis, incomplete arteriovenous malformations closure, late onset of arrhythmias and late device related thrombus formation). There were four deaths (0,97%). Overall success rate in this patient’s cohort was 96.9% all over a period of 12 months follow up for the patients.ConclusionConsiderable percentage of patients with CHD undergoing transcatheter interventional percutaneous procedures with off-label implantation of devices or stents. These procedures have high success rate and relatively low incidence of complications. So Longer term follow-up is needed in order to establish safety and effectiveness of these off-label procedures in congenital heart defects.Key words: Off label devices, Stents, Percutanous Introduction Off label use of medications and devices is relatively common among pediatric population. This can be explained by the small number of pediatric patients compared to adults that can be enrolled in randomized clinical trials designated to evaluate the safety and efficacy of either drugs or devices [1]. Furthermore, the wide variety and morphological complexity of congenital heart disease (CHD) make the design and evaluation of dedicated therapies intended for these rare pediatric conditions too expensive. CHD are considered among this category which makes the development of specific devices very unlikely [2]. Recent major advances in cardiac imaging, especially 3-dimesnional (3D) echocardiography, computed tomography (CT) with high spatial resolution and ability of 3 D reconstruction, rotational and 3-dimenional (3D) cineangiography, recent software with artificial intelligence (AI) and ability to simulate behavior of devices and stents after implantation have made catheter based interventions an alternative method for the treatment of CHD rather than surgery with high rate of success and good procedural outcomes. The increased prevalence of catheter intervention in CHD has raised the need for the off-label use of devices and stents (i.e. the use of the devices in ways other than their intended applications mentioned in the instruction of use (IFU)) in these procedures [3]. Although it is possible to manufacture devices designed for those specific lesions or add new approved indications for the already existing devices, both of these processes are expensive and time consuming [4]. While relatively few cardiac devices have received FDA approval in children, the number of devices navigating the approval process successfully is growing. Most pediatric device approvals are being granted through the humanitarian device exemption (HDE) pathway, which is designed for rare diseases making it suitable for devices treating congenital heart disease [5]. Patients and methods A retrospective data collection involving all patients who were referred to the congenital and structural heart disease unit in Ain Shams hospitals which is a tertiary center and considered as one of the 3 largest congenital and structural heart disease centers in Egypt. We included all patients during the last 4 years from January 2019 to January 2024. All interventional procedures were carried out by certified, well-trained physicians experienced in congenital and structural heart interventions. Interventional imagers guided the procedures by way of 2D and 3D transthoracic and transesophageal echocardiography when indicated, Multi-slice cardiac tomography (MSCT) and cardiac Magnetic resonance imaging (MRI) were used in the diagnosis, evaluation, preplanning and intra-procedural catheter intervention guidance with CT overlay when needed. Off label use of devices and stents was defined in this study as the use of approved medical devices and stents in transcatheter interventional procedures for indications other than the ones approved in the instructions for use (IFU) manual, FDA or CE mark, disregarding the age of the patient as shown in figure 1. Incidence of different type of congenital heart disease treated by off-label device implantation We considered balloon expandable stent implantation in great vessels as an on-label device use as we commonly implant them in either aortic coarctation and peripheral pulmonary artery stenosis, despite they have not been approved as an on-label use for these two indications. Data collection included demographic data, preprocedural diagnosis and imaging data with focus detailed echocardiographic assessment for the targeted lesions and biventricular functions, MSCT with 3-D reconstruction of the heart and great vessels and mediastinal structures including the airway, cardiac MRI when needed and indicated were also included especially in the evaluation of right ventricular volumes and functions, shunt evaluation and valvular regurgitation quantification. Procedural success and failure were recorded independently. Procedural failure was defined as failure to implant the device or the stent or the need of immediate surgical intervention. Early and late complications were also recorded and included vascular access, procedure and device related complications. We also calculated the percentage of both the off-label use and the failure rates in each procedure and the different types of devices used in them. Data was collected and analyzed using IBM SPSS version 27, data were tabulated and represented in figures. Results Patients demographics A total number of 2530 percutaneous CHD interventions were performed in our institution in the last 4 years of which a total number of 1905 interventional procedure with device/ stent implantation. Off-label device/stent implantation was performed in 410 procedures (21.5%). In almost all of them a device or stent was implanted in an off-label situation. Devices were implanted in 360 procedures (87.8%) and stents were implanted in 50 procedures (12.2%) Fig. 1.The mean age was 6.70 ± 4.47 years, the mean body weight was 18 0.3 +/- 8.5 kg ranging from 2.2 kg up to 95 kg. Table 1. Table 1Demographic data for patients under went off label device/ stentOff label useNumberN = 410Per = 21.5%AgeMean 6.70 ± 4.47 yrsR = 7 days – 30 yrsSex Males Females237173Per58%42%weightMean 18.3 +/- 8.5 kgR = 2.2–95 kgBSAMean 0.85 +/- 0.4 m2/kgR = 0.25–1.9 m2/kgType of lesions using devices VSD PDA V-V collaterals AP collaterals Coronary AV fistula Others un classifiedN = 360N = 285N = 10N = 16N = 10N = 13N = 26P = 87.5%Type of lesion using stents PDA stenting RVOT stenting IAS stenting SVC stenting MBT shunt stenting SV baffle stentingN = 50N = 38N = 6N = 2N = 1N = 1N = 1P = 12.5%Previous catheter or surgical interventionN = 110P = 27%Biventricular anatomyUniventricular anatomyN = 350N = 60P = 86%P = 14%VSD: ventricular septal defect, PDA ( persistent ductus arteriosus), V-V ( venovenous ), A-P ( aortopulmonary) Demographic data for patients under went off label device/ stent Males Females 237 173 Per 58% 42% Type of lesions using devices VSD PDA V-V collaterals AP collaterals Coronary AV fistula Others un classified N = 360 N = 285 N = 10 N = 16 N = 10 N = 13 N = 26 Type of lesion using stents PDA stenting RVOT stenting IAS stenting SVC stenting MBT shunt stenting SV baffle stenting N = 50 N = 38 N = 6 N = 2 N = 1 N = 1 N = 1 Biventricular anatomy Univentricular anatomy N = 350 N = 60 P = 86% P = 14% VSD: ventricular septal defect, PDA ( persistent ductus arteriosus), V-V ( venovenous ), A-P ( aortopulmonary) Clinical presentation and indication for intervention are shown in Table 2. Table 2Indications for intervention and clinical presentationNumber ( %)Clinical presentation Failure to thrive Recurrent chest infection Dyspnea cyanosisN = 156 ( 38%)N = 40 ( 9.7%)N = 164 ( 40%)N = 50 (12.5%)Indications for intervention Emergency procedure Symptomatic patients Dilated cardiac chambers Significant shunt fraction (Qp/QS > 1.5 ) Increased cyanosis (desaturation < 75%)N = 40 ( 9.7%)N = 348 ( 85%)N = 336 ( 82%)N= 328 (80% )N = 62 (15%) Indications for intervention and clinical presentation Failure to thrive Recurrent chest infection Dyspnea cyanosis N = 156 ( 38%) N = 40 ( 9.7%) N = 164 ( 40%) N = 50 (12.5%) Emergency procedure Symptomatic patients Dilated cardiac chambers Significant shunt fraction (Qp/QS > 1.5 ) Increased cyanosis (desaturation < 75%) N = 40 ( 9.7%) N = 348 ( 85%) N = 336 ( 82%) N= 328 (80% ) N = 62 (15%) Procedural details and devices used Regarding some procedural details, we did 40 urgent procedure mostly for neonates, some of them were mechanically ventilated or dependent on IV prostaglandins, all vascular access options were utilized with most commonly used right femoral artery and right femoral vein, with mean procedural time of 90 +/- 33 min and mean fluro time of 45 +/-15 min as shown in Table 3, device types are shown in Table 4. Table 3Procedural detailsNumberVascular accessFemoral artery (Rt/ Lt )Femoral vein (Rt/ Lt )carotid artery (CCA)Axillary artery ( Lt)Internal jugular vein( Rt)Subclavian vein (Rt)N = 361N = 320N = 20N = 3N = 10N = 16Procedural timeMean 90 +/- 33 minFluro timeMean 45 +/-15 minApproachRetrogradeAntegradeN = 102N = 265 Procedural details Femoral artery (Rt/ Lt ) Femoral vein (Rt/ Lt ) carotid artery (CCA) Axillary artery ( Lt) Internal jugular vein( Rt) Subclavian vein (Rt) N = 361 N = 320 N = 20 N = 3 N = 10 N = 16 Retrograde Antegrade N = 102 N = 265 Table 4The proportion of off-label uses in transcatheter interventions for congenital heart disease with device implantationInterventionTotal casesOff-label ( N& %)Off label device and their numberVSD closureGerbode defect 295 285 ( 95%) 6/285 ( 2%) MFO 158, (ADO I, cera PDA, Memopart PDA ) 120, 10 muscular VSD.MFO 5, 1 muscular VSDPDA closure 380 10 (2.6%) Muscular VSD 4, MFO 2, cera vascular plug 2Venovenous collateral 16 16 (100%) (ADO I and II, cera PDA, Memopart PDA) 12, cera vascular plug 2, cook coil 2Aortopulmonary collateral 10 10 ( 100%) ( ADO I, ADO II ) 6, cera vascular plugs 2, embolization coil 2Coronary AV fistula 13 13 ( 100%) ( ADO I, ADO II, cera PDA) 7, Konar MFO 2, cera ASD 1, muscular VSD 2, AVP II 1, embolization coils 1AV malformation 6 6 (100%) (ADO I, ADO II ) 2, AVP II 2, embolization coils 2.Paravalvular leakks 4 4 ( 100%) muscular VSD 2, cera vascular plug1, ADO I 1Others 16 16 (100%) PDA stenting 38 38 ( 100%) Coronary stents 38 ( from 3–5 mm) RVOT stenting 6 6 ( 100%) Coronary stents 6 ( 4.5–5.5 mm) IAS stenting 2 2 ( 100%) Valeo stents SVC stenting 2 2 ( 100%) CP stents 2 Others 2 2 ( 100%) PDA: patent ductus arteriosus, VSD: ventricular septal defect, AVP: amplatzer vascular plug, ADO: amplatzer ductal occlude The proportion of off-label uses in transcatheter interventions for congenital heart disease with device implantation VSD closure Gerbode defect 285 ( 95%) 6/285 ( 2%) MFO 158, (ADO I, cera PDA, Memopart PDA ) 120, 10 muscular VSD. MFO 5, 1 muscular VSD PDA: patent ductus arteriosus, VSD: ventricular septal defect, AVP: amplatzer vascular plug, ADO: amplatzer ductal occlude Outcomes and follow up There were 4 deaths (2 cases of PDA stenting in ductal-dependent pulmonary circulation patients, one coronary AV fistula closure and one RVOT stenting). Retrograde analysis of data showed that the main factors which contributed to these mortalities were; the pre-procedural poor general condition of the patient with high-risk features, urgent procedure timing secondary to the critical patient’s condition, extremely low birth weight, severe oxygen desaturation and metabolic derangement, One case underwent the procedure with pre-procedural resuscitation in the neonatal intensive care unit (NICU). The coronary AV fistula closure case was complicated by retro-grade extension of thrombosis, myocardial infarction (MI) and then Intra-cranial hemorrhage secondary to fibrinolytics given to treat the acute MI. Major and minor complications were reported in 13 cases. Major complications included device embolization in 3 patients, one retrieved percutaneously and 2 surgically removed with defect repair. Stent implantation failed in 4 cases due to either malposition or embolization, Table 5. Six minor complication included device encroachment on LPA origin with mild gradient detected by echocardiography, device interference causing increase of tricuspid (TR) regurgitation and new onset mild aortic regurgitation (AR), residual VSD in 1 case with incomplete defect closure, one case of residual arteriovenous malformation, one case of delayed arrhythmia and one case of delayed thrombus formation on the device. In addition to vascular access complications which accounted for 2.5% of the case Table 6. All patients were followed up for at least 12 months, however the above mentioned complications either occurred intraoperatively or shorty within 48 h before discharge, however no complications were detected in the short or mid term follow up period. Table 5Clinical success rates of the off-label use for each procedure and a comparison of each procedureProcedureCasesSuccessVSD closure 285 282 ( 99%) PDA closure 10 10 ( 100%) Vaenovenous collateral 16 16 ( 100%) Aortopulmonary collateral 10 10 ( 100%) Coronary AV fistula 13 12 ( 93%) Paravalvular leak 4 4 ( 100%) PDA stenting 38 34 ( 90%) RVOT stenting 6 6 ( 100%) SVC stenting 2 2 ( 100%) Mortality 4 0.9% Morbidity (major or minor complications) 13 3.1% Clinical success rates of the off-label use for each procedure and a comparison of each procedure Table 6Procedural failures either during or after a procedureCauses of failureUnderlying diseaseProcedureDevice implantation9/360 = 2.5% 3 cases of device embolization VSD closure with MFO and ADOI 1 residual VSD VSD closure with MFO 1 mild encroachment of TV VSD closure with muscular VSD 1 minor aortic cusp injury VSD closure using MFO deployed from arterial side 1 Transient AV block VSD closure using ADO I 1 mild encroachment of the device on LPA Hypertensive PDA using muscular VSD 1 residual AV malformation closed later on Using embolization coil Stent implantation4/ 50 = 8% Stent embolization 2 PDA stenting Stent malposition 2 PDA stenting Total 13 Procedural failures either during or after a procedure Device implantation 9/360 = 2.5% Stent implantation 4/ 50 = 8% Off label use of devices Ventricular septal defect (VSD) closure From a total number of 295 VSD closure procedures, 285 (96.6%) had an off-label device closure while the remainder 10 cases had on-label closure with Amplatzer Muscular VSD Occluders. Perimembranous VSD were closed with off-label devices, as follows: type 1 or type 2 Amplatzer Duct Occluders (ADO) (Abbot), Cera PDA devices (Lifetech Medical), Memopart PDA devices (Lepu Medical), and Cera Muscular VSD Occluders (Lifetch Medical) in 120 patients. Another 145 patients had their VSD closed using Konar MFO Occluder devices (Lifetch Medical) and one small ASD device was used in one patient. Muscular VSDs were closed with Konar MFO Occluders (Lifetech Medical) in 10 cases, either iatrogenic or congenital Gerbode’s defects were also closed with Konar occluder in 5 cases and with Cera Muscular VSD occluder in one case. Subpulmonic VSDs were closed using ADO 1 occluder in 3 case Fig. 2F. Off label use of VSD using MFO, ADO I and muscular VSD device The choice of single disc versus double disc device, or the choice between different single disc and different double disc devices was based on multiple factors; mainly the anatomical feature of the defect, the presence or absence of tissue aneurysm, the number of opening in the tissue aneurysm in the right ventricular side, the proximity to the aortic valve, the baseline tricuspid regurgitation, the body weight of the patient, the operator experience and preference to a particular device, the softness of the device and size of delivery sheath and to lesser extent the availability of the devices. Patent ductus arteriosus (PDA) closure A total 380 patients underwent PDA transcatheter closure, only 10 procedures were done using off-label devices including muscular VSD devices in four patients with hypertensive PDA, Cera vascular plug in two patients due to relatively long length of the ductus arteriosus and presence of distal constriction, Konar MFO in three patients, and ASD device in one patient. Fig 1; Table 4. Double disc devices were all used in relatively older patients with large PDA ampulla and dilated pulmonary tree with no risk of iatrogenic induction of coarctation or pulmonary artery stenosis by one of the device discs. The presence of pulmonary hypertension also was a reason for choosing of double disc devices, large size of PDA beyond the available single disc duct occlude device ( ADO-I or devices with similar design was a cause in two patients). Venovenous collateral closure A total number of 16 cases of veno-venous collaterals closure post Glenn shunt operation were done successfully using either detachable Cook coils, ADO-I, ADO-II, cera PDA devices, muscular VSD or ASD device. The choice of the device used was mainly based on the size of the venous collateral, presence of tortuosites in them, the size of delivery sheath in comparison to the patient’s body weight and the availability of the devices. Vascular plugs were not used as they are rarely available in our country. Coronary AV fistula closure Thirteen cases with coronary AV fistula/ coronary cameral fistulae-with proximal or distal origin from Right coronary artery (RCA), left circumflex artery (LCX) and left anterior descending artery (LAD)- with variable sizes, single or multiple end openings into the right atrium (RA), right ventricle ( RV) and left ventricle (LV) and coronary sinus (CS) were closed using different type of off-label devices based on the anatomy, size of the fistulous track, site of fistulous track constriction if present, and site of opening and size of the delivery sheath of the device and the chosen method of closure ( antegrade versus retrograde, i.e. forming a loop and closure from venous side or closing directly from arterial side without arterio-venous loop formation) using ADO-I, ADO-II, Cera PDA device, Konar MFO, Cera ASD device, muscular VSD device, Amplatzer vascular plug (AVP)-II and detachable Cook embolization coils Fig. 3. Coronary AV fistula closure using Muscular VSD and cera PDA Aortopulmonary collaterals closure We did also various types of Aortopulmonary collaterals and major aorto-pulmonary collaterals (MAPCA) closure (10 cases) using detachable coils in the small ones and ADO-I, ADO-II and Cera vascular plugs in larger ones. We choose the device size about 40% more than the diameter of the collateral and we used bilateral arterial femoral access for device deployment and control injections in 4 cases. Other interventional procedure Ruptured sinus of Valsalva were closed in 6 patients with ADO1, Cera PDA Occluder, Cera ASD Occluder and Konar MFO Occluder. Six patients with pulmonary AV malformations/ fistulae presented with desaturation and decrease effort tolerance and/or cyanosis were closed using detachable embolization coils, ADO-I, ADO-II and two cases with vascular plugs (AVP II). Four patients had isolated pulmonary AV malformation/fistulae and two cases had Osler weber Rendo Syndrome. One case of recanalized Modified Blalock-Taussig Shunt after a Glenn Shunt, was occluded using ADO 1 8 × 6 mm device. A case of aortopulmonary window closure using large konar MFO device 14 × 12 mm, A case of fistulous connection between the ascending aorta and main pulmonary artery (MPA) closure by konar MFO 10 × 8 mm. A case of fistulas connection between right pulmonary artery and left atrium (LA) closed using muscular VSD 10 mm. We also closed pulmonary artery (PA) aneurysm, A calcified PDA aneurysm post-surgical ligation with muscular VSD device 10 mm and MFO konar occluder 14 × 12 mm respectively. Two cases of persistent levoatrial cardinal vein (LACV) were closed by by cera vascular plug and ADO I devices. A cases report of anterior mitral valve leaflet (AMVL) perforation post-surgical resection of recurrent subaortic membrane was closed using a Cera ASD device 6 mm. Four cases of Paravalvular leakage (PVL) closure in congenital heart disease patients with mitral or aortic valve replacement due to congenital mitral stenosis or bicuspid aortic valve and Kono-operation or pulmonary valve replacement post RVOT reconstruction and bioprothesis implantation (two cases of mechanical Mitral valve PVL, one case of mechanical aortic PVL and one case of bioprosthetic pulmonary valve PVL were closed using muscular VSD devices, Cera vascular plug and ADO-I device. Off-label use of stents PDA stenting PDA stenting in patients with complex congenital heart disease and duct dependent pulmonary circulation using balloon expandable coronary artery drug eluting and bare metal stents in 39 patients. Different vascular accesses were used including femoral arterial access, femoral venous access, trans-carotid and trans-axillary accesses, Diameters of implanted stents varied from 3 to 5 mm according to the patient’s body weight and the size of the peripheral pulmonary tree and size of the PDA itself. Right ventricular outflow tract (RVOT) stenting Six cases of successful RVOT stenting mostly with large diameter coronary stents ranging from 4.5 mm to 6 mm. Only transthoracic echocardiographic guidance and fluoroscopy were used together to avoid contrast injection in critically ill neonates Fig. 4. Showing RVOT stenting using coronary stent and IAS stenting using valeo stent Other off-label stenting Different types of stent procedures were used in 6 other patients.Two patients underwent interatrial septal stenting using balloon expandable peripheral stents Fig. 4. They had mitral valve atresia and closing interatrial shunt with severe pulmonary hypertension and /or reduction of cardiac output. CP stents were used in another two patients post-surgical repair of sinus venous ASD and anomalous pulmonary veinous drainage complicated by severe SVC stenosis and superior vena cava syndrome. Another patient had systemic venous baffle stenting in post-op atrial switch operation and venous baffle stenosis using uncovered CP stent. 4.5 × 18 mm coronary stent was implanted in a MBT shunt, due to early post-surgical shunt thrombosis. Table 1. Discussion Our registry showed 21.5% of the total patients underwent off label device or stent implantation with overall success rate of 96.5%. This relatively high percentage of patients who received off label device or stent reflects the real-world practice in our center, and shows clearly that these patients are no longer a rare entity and constitute a considerable amount of the total patients and procedures done every day. In the paper published by Kong et al.; they have found that off label medical devices implantations accounted for only 8.3% of their pediatric cardiac interventions, he also reported an acceptable clinical outcome with 93.8% overall success rate among their cohort. Other studies and registries reported incidence of off-label procedures ranging from 3.9% up to 15% [4, 6]. This difference in the incidence and prevalence of the off-label device implantation procedures between our registry and previously published data can be attributed to many factors. First of all, the absence of unified, widely accepted definition of the term off-label use of devices and stents among different reports with the variable inclusion and exclusion criteria used in each of them, second the different practice among different countries, also the difference in the cardiothoracic department capabilities in each center and country and the type of procedures done surgically and the length of the surgical waiting list and the mean waiting time until the patients have their surgery done, this may shift many patients from the long surgical waiting list to transcatheter option. We would like also to mention that recent advances in the technology of the devices design and materials used in manufacture of these devices in recent years with the introduction of new devices with new designs in the market and softer and thinner nitinol mesh like for example Konar MFO have made it possible to use it in an off label in different lesion. We do not also ignore the recent major advancement in 3 D echocardiography and wide use of MSCT with 3 D reconstruction in pre-procedural planning that allowed us to perform more complex procedures with better procedural planning and lower incidence of complications. Surgical outcomes can have a significant contribution to the different prevalence of these procedures, as redo-surgery is usually not recommended to the patient’s family as a treating option for residual surgical lesions or for short- and long-term surgical complications either due to refusal of the surgeon deeming it as high-risk procedure or refusal of the parents or the patient himself to undergo another surgical procedure with long and hard recovery. Some patients in our registry have residual post-surgical shunts including residual VSDs [3, 6]. Off-label use of devices and stents is not uncommon in real world practice due to multiple factors. The wide variety of congenital heart disease, compared to acquired diseases of adult population makes it time consuming and less cost effective to have dedicated devices specifically designed and approved for each and every type of congenital heart defect [7, 8]. In our study, we had a larger number of VSD cases and we used new innovative devices that were recently available in our country and in the global market, these devices had a great impact on the VSD closure procedural success and had also expanded the number of the patients suitable for transcatheter closure. It was well known that peri-membranous and muscular VSDs could be closed off-labely using ADO I with good success rate [9]. Our study added a great proportion of patients that were closed safely and effectively using the Konar MFO device with low incidence of complications 1.7% so we recommend that this device can be used on label for peri membranous VSD closure. Our result are comparable to Rymond et al. who reported overall success rate of PM VSD using Konar MFO device 97.6% with very low incidence of complication [10]. The most common indications for off label device use in PDA were hypertensive ductus needing double disk devices to prevent single disk device embolization. Muscular VSD devices or Konar MFO occluders were used. Long, tubular PDA were closed using Amplatzer Vascular Plugs (AVP) [11, 12]. Coronary AV fistulae are always closed using different devices depending on anatomic variation and characteristics [13]. In our study we used different devices as muscular VSDs, ADO-I, ADO-II, Konar MFO and ASD devices with 93% success rate. 85% of the cases were closed antegradely and 15% were closed retrogradly. Complications included two cases with device migration, one case with coronary spasm, one case of coronary thrombosis and myocardial infarction. Similar to our result, Rymond et al. reported closure of medium- or large-sized CAFs with the use of coils (30%), vascular plugs (20%), nitinol duct occluders (40%), or material combination (10%), Six serious complications occurred. Two of the 3 patients with unsuccessful catheter procedures had subsequent surgeries. Two of the 3 patients with mild shunts had successful redo closures. One asymptomatic patient had recanalisation after 12 years and is under watchful observation [14]. A total number of 16 cases of successful venovenous collateral closure in patients after partial cavo-pulmonary connection (PCPC) were performed as surgical palliation for patients with functionally univentricular heart. These patients had a significant rise in their transcutaneous oxygen saturation post procedure and hence, a clear clinical benefit. Cook coils were used in small collaterals, however ADO-I, ADO-II and Cera vascular plugs and other double disc devices were used to close larger venovenous collaterals. Abdelaziz et al. reported 9 successful cases of venovenous collateral closure with baseline significant desaturation using either Amplatzer vascular plug I and II also they reported the use of multiple coils as cook coils, Gianturco coils and the new detachable hydrogel [15]. Isolated Aortopulmonary (AP) collaterals are rare but commonly seen in patients with cyanotic congenital heart disease with decreased pulmonary blood flow. We report successful transcatheter closure of 10 cases with isolated aortopulmonary collaterals and structurally normal heart after confirming dual blood supply for the supplied lung segments. We closed smaller ones using Cook coils and larger ones with ADO-I, ADO-II or Amplatzer vascular plug I or II. Khelashvili et al. reported the closure of large isolated MAPCAS with multiple branches using different sizes of Amplatzer vascular plug II [16, 17]. Stents are generally considered on-label for use in great vessels stenting as coarctation and pulmonary artery stenting, that is why we did not include these patients in our registry as off label use of devices. PDA stenting is one of the most challenging pediatric catheter interventions with few case series reported in literature. We reported 39 cases of PDA stenting with overall success rate of 90%. Two cases of mortality due to poor general condition of the patient, 2 cases with malposed stent due to slippage of the stents in the right pulmonary artery (RPA) with the need of another overlapping stent. We also reported six cases of successful RVOT stenting using large coronary stents 4.5–5 mm with significant improvement in oxygen saturation compared to baseline values [18, 19]. While RVOT stenting has been introduced recently in our center, our patients were successfully treated with high success rate and this could be attributed to the good pre-procedural MSCT, echocardiography and good procedural planning [20]. Abaqri et al., reported the use of coronary stents for smaller children and neonates for short term palliation and bare metal peripheral vascular stents- preferably cook formula premounted stents- in RVOT stenting for older children or those who required long term palliation [21]. The overall success rate in our study of all off-label device and stents procedures was 96.9%. While Young Hwa Kong, reported in his study an overall success rate of 93.3% with immediate and late failures from off-label use of devices were identified in 9 cases (6.3%); 7 operations and 2 re-interventions were performed in these patients. There were 10 minor and transient complications, such as arrhythmia, thrombus formation, and embolization, related to the procedures. Three cases of mortality not directly related to the device were also detected. The Off label use of devices varies from one Centre to another depending on operator preference and experience, availability of some devices or cost-effectiveness. Rymond et al. reported the use of microvascular plugs for different vascular abnormalities in children with CHD as PDA, coronary AV fistula, venous collaterals or MAPCAS with overall procedure success rate of 96.7% [22]. Novel devices and stents are being tested where Raymond N Haddad tries to safely implant Optimus L stent in small infants with a low profile approach.[23]. Currently there are dedicated trials studying the use of absorbable devices and stents in patients with congenital heart disease such as bioabsorbable ASD and VSD devices [24]. Conclusion Off-label use of devices and stents represents one out of five patients in our cohort. Success rate of these procedures are high, with acceptable complication rates. Longer-term follow-up is needed in order to establish safety and efficacy of off-label procedures in congenital heart defects. Limitations Our report had various limitations, being a retrospective study conducted in a single institution, and it therefore cannot represent the current status of all patients in our country. Devices were used mainly according to availability and sometimes according to operator preferences which could differ widely across different centers, and the short term follow up of patients. Acknowledgements Not applicable. Author contributions AN: Has took part in: conception and design of the study, performing the echocardiographic analysis, catheter intervention, transesophageal echocardiography and interpretation of the data, drafting of the manuscript and final approval of the manuscript submittedME: Has took part in: conception and design of the study, performing the statistical analysis and data interpretation for patients included in the study group, revising the manuscript critically for important intellectual content and final approval of the manuscript submittedAE: Has took part in: conception and design of the study, performing the echocardiographic analysis, catheter intervention, transesophageal echocardiography and interpretation of the data, drafting of the manuscript and final approval of the manuscript submittedHA: Has took part in: conception and design of the study, performing the echocardiographic analysis, catheter intervention, transesophageal echocardiography and interpretation of the data, drafting of the manuscript and final approval of the manuscript submittedAR: Has took part in: conception and design of the study, performing the echocardiographic analysis, catheter intervention, transesophageal echocardiography and interpretation of the data, drafting of the manuscript and final approval of the manuscript submittedYA: Has took part in: conception and design of the study, performing the echocardiographic analysis, catheter intervention, transesophageal echocardiography and interpretation of the data, drafting of the manuscript and final approval of the manuscript submitted.AM: Has took part in: conception and design of the study, performing the echocardiographic analysis, catheter intervention, transesophageal echocardiography and interpretation of the data, drafting of the manuscript and final approval of the manuscript submitted. Funding Not applicable. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate Approval of Ain Shams University ethical committee was given for the study. Informed consent was obtained from all infants guardians. All the patients in the master table, coded by numbers to preserve their confidentiality and no one has right to read the patient medical information except the main researcher. Data collected in this study are in line with the Helsinki Declaration. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.